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Message from the Director of Oncology
Dear Colleagues,
Childhood cancer is diagnosed in 12,400 children
annually and 2,500 die from cancer each year (SEER
data as of 1998). A child born today has a 1 in 300 risk
of developing cancer during his or her first 20 years of
life. It is the fourth most common cause of death in
children, trailing unintentional injuries, homicide and
suicide. This year’s issue of the Children’s Mercy
Hospital Cancer Center Annual Report highlights
osteosarcoma, a cancer that accounts for about 56% of
the bone tumors in children. Bone tumors comprise the
fourth most common solid tumor of childhood.
Through the efforts of a well-coordinated
multidisciplinary team approach we have seen
significant improvements in survival. SEER data from
1975-1984 and 1985-1994 show five year survival rates
of 42% and 58%, respectively. A comprehensive cancer
center is essential to the coordination of the various
services involved in the treatment/evaluation of a child
being treated for cancer. These services include, but are
not limited to, orthopedic surgery, pathology,
cytogenetics, radiology, and oncology. As you will see in
this year’s report we are fortunate to have such a
comprehensive center at Children’s Mercy Hospitals and
Clinics. Children’s Mercy is a major institution in the
Children’s Oncology Group (C.O.G.), the national NIHfunded cooperative clinical trials group for children with
cancer. C.O.G. has several trials investigating treatment
options to further improve the cure rate and quality of
life for children as survivors of osteosarcoma. Children
with osteosarcoma at Children’s Mercy have access to a
comprehensive team of experts from across the country,
the latest national trials, and the most current
information regarding best treatment options.
Osteosarcoma is a disease primarily of
adolescents/young adults, with peak years of risk
between 11 and 19 years of age, nearly half occurring
between 15 and 19 years of age. This affords me the
opportunity to focus on a long-standing problem and
one that is even more critical after a recent report was
published. A small percentage of adolescents are
referred to pediatric cancer centers (A recent analysis
demonstrated that >94% of children are treated at a
specialized NIH cooperative group site that is associated
with a pediatric cancer center. However, only 21% of
adolescents between age 15 and 19 are seen at such
centers.). Childhood cancer cure rates have
dramatically improved over the past several decades, in
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large part because of the multidisciplinary, pediatric-focused
cancer centers, nearly all
associated with the NIH
sponsored cooperative trials
groups. Adolescents have been the group to receive the
least benefit. From 1973 to 1992, death from cancer
had the smallest decline in the 15 to 19 year old age
group among all children with cancer - 33% compared
to 47% for children age 0-9 years. This, in conjunction
with the fact that children <21 years of age have
demonstrated an increase in the incidence of cancer,
nearly 31% in the age group of 15-19 years of age.
This is compared to an 8% increase in children of a
younger age that further identifies this as a critical
problem. Close to our topic is Ewing’s sarcoma, the
other major bone tumor in children, with outcomes that
demonstrate a higher cure rate when treated with
pediatric cooperative group trials as compared to those
who were not. Clearly, the word must be spread that the
adolescent with cancer has the best chance for cure
when treated at a pediatric cancer center. This year’s
focus on osteosarcoma highlights the improved cure
rates associated with osteosarcoma and, additionally,
the positive impact that a comprehensive pediatric
cancer center has on improved survival.
A final note for this year’s report would be the
development of the Children’s Mercy Cancer Center
website. It was established this past summer; when fully
functional, it will serve our patients/families and our
referring physicians/care providers in the community.
The focus of this website, but not limited to, is cancer
prevention, cancer treatment options, supportive care,
as well as resources available to support our community
at-large in the treatment of pediatric cancer.

Sincerely
Sincerely,,

Alan SS.. Gamis, MD
MD,, MPH
Chairperson - CMH Cancer Care Committee
Director of Oncology, Children’s Mercy Hospital

Message from the President/CEO
Dear Colleagues,
Children’s Mercy Hospitals and Clinics is proud to
be accredited by the American College of Surgeons and
to be a nationally recognized cancer center. It has been
amazing to see the improvements in treatment
regimens, as well as improved outcomes over the years
and knowing that Children’s Mercy has taken part in
this success. We take great pride in honoring the family
throughout a course of treatment. The diagnosis of
cancer truly impacts the entire family. Thus, a holistic
approach is our goal in striving to maintain the healthy
dynamics of each family as they progress through this
unfamiliar journey.
This report presents information regarding the
activity specific to Children’s Mercy and, more globally,
our relationship to national survival rates. It is our goal
to continue to keep you informed of our progress in
fighting childhood cancer. The 2000 Annual Report
focuses on a bone disease, osteosarcoma, that
although seen less frequently than other childhood
cancers, poses unique challenges. The unusual aspect

of this tumor is that it affects
adolescents primarily. This is a
population of patients with
specific needs very different from children of younger
ages. How courageous these adolescents are and
what an honor it is to support them. I am pleased to
share with you this year’s Cancer Care Annual Report.

Sincerely
Sincerely,,

Randall L. O’Donnell, PhD
President / Chief Executive Officer

Children’s Mercy Hospital
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Cancer Registry Data
Objectives

Benign and Borderline Tumors

• To collect and maintain data on all patients diagnosed
and treated with malignancy and selected benign and
borderline tumors at Children’s Mercy Hospitals and
Clinics.
• Abstract data which includes information on cancer
type and location, stage or extent of disease at
diagnosis, treatment received, recurrence, and followup information.
• Provide data to physicians, Missouri Cancer Registry,
and the National Cancer Data Base for improving the
prognosis for cancer patients.
• Participate and organize the approval process for
accreditation from the American College of
Surgeons Commission on Cancer (ACOS).
Accreditation was granted in July 1999.

• These tumors are included in the registry by agreement
of the Cancer Care Committee.
• Determination for inclusion is the location of the tumor
(e.g. central nervous system) or its propensity to recur
and/or progress to malignancy.
• Five Benign and Borderline Tumors were reported
for 2000 (Fig. 2).

Class of Case and Follow-Up
(ACOS-COC Classification) - Fig. 2
• During the abstracting process a class of case is
assigned according to the criteria set forth by the ACOS.
• Case 0 includes patients diagnosed at CMH but
received all of their first course of treatment
elsewhere. In 2000 there were 0 cases reported.
• Case 1 includes patients diagnosed at CMH and
received all of their first course of treatment at CMH.
In 2000 there were 77 class 1 cases reported.
• Case 2 includes patients diagnosed elsewhere and
received all or part of their first course of treatment
at CMH. In 2000 there were 14 class 2 cases
recorded.
• Case 3 includes patients diagnosed elsewhere who
receive their first course of treatment at another site/
center. In 2000 1 class 3 case was recorded.
• Case 0-2 are followed annually to determine survival
and disease status.
• Follow-up rate
• 84 percent of all CMH cancer registry patients had
their disease status updated by the end of 2000.
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Reference Date
• The Commission on Cancer (COC) of the American
College of Surgeons requires a start date for data
collection to begin. This date is controlled by the facility,
but approved by the COC. Therefore, the Children’s
Mercy Hospital Cancer Care Committee commissioned
a change in the reference date to ensure data quality.
• January 1, 1978 was the original reference date at
Children’s Mercy Hospital.
• January 1, 1990 is currently the reference date for
Children’s Mercy Hospital effective April 17, 2001.

2000 Registry Statistics:
(January 1, 1990 Reference Date)
• 893 patients are abstracted in the cancer registry since
1990.
• 97 patients were added to the registry in the year 2000.
• Frequency of Diagnosis for 2000: (see Fig.1)
• Five most frequently occurring diagnoses for 2000
- Leukemia
- Brain Tumors
- Lymphomas
- Wilm’s Tumors
- Osteosarcoma

Cancer Registry Data
Children’s Mercy Hospital Cancer Registry 2000 Frequency of Diagnosis - Figure 1
Leukemia
ALL
AML

19
5

Central Nervous System
Astrocytoma
Medulloblastoma
Anaplastic Benign/Borderline
Glioma
Ependymoma
Germinoma
Neuroectodermal Tumor

6
1
9
1
1
1
3

Lymphoma
Non-Hodgkin’s
Hodgkin’s

9
7

Wilm
’s TTumor
umor
Wilm’s

24

22

(25%)

(23%)

16

(17%)

7

(7%)

Class of Case (ACOS-COC Classification)
Figure 2
Class 0
0
(0%)
Diagnosed at CMH - received all of first course of treatment elsewhere.
Class 1
77
(79%)
Diagnosed at CMH - received all of first course of treatment at CMH.
Class 2
14
(14%)
Diagnosed elsewhere - received all or part of first course of treatment at CMH.
Class 3
1
(1%)
Diagnosed elsewhere - received all of first course of treatment elsewhere.
Benign
5
(5%)
Included in the Registry due to location (tumor of central nervous system),
or because of its propensity to recur.

Osteosarcoma

6

(6%)

Neuroblastoma

4

(4%)

Rhabdomyosarcoma

4

(4%)

14

(14%)

Other
Retinoblastoma
Carcinoma NOS
Desmoplastic Small Round Cell
Ewing’s Sarcoma
Hepatoblastoma
Melanoma
Clear Cell
Germ Cell
Nerve Sheath Tumor
Rhabdoid
Total Number of Cases for Y
ear
Year

3
2
1
2
1
1
1
1
1
1

97

Class of Case (A
COS
(ACOS
COS-- COC Classification)
Mortality Data - Figure 3
Central Nervous System
Astrocytoma
Medulloblastoma
Glioma
PNET
Pineoblastoma

12
2
3
2
4
1

Acute Lymphoblastic Leukemia

4

Acute Myeloid Leukemia

1

Lymphoma
Non-Hodgkin’s
Hodgkin’s

3
1

4

Neuroblastoma

3

Osteosarcoma

1

Rhabdomyosarcoma

3

Total Number of Mortalities in 2000

28

7

8
Central Nervous System 22
Leukemia 28

Lymphoma 8
Neuroblastoma 9
Wilm
’s TTumor
umor 1
Wilm’s
Rhabdomyosarcoma 2
Osteosarcoma 1
Others 8

Total Cases
97

Central Nervous System 33
Leukemia 24
Lymphoma 11
Neuroblastoma 8
Wilm
’s TTumor
umor 4
Wilm’s
Rhabdomyosarcoma 6
Osteosarcoma 4
Others 10

Central Nervous System 25
Leukemia 21
Lymphoma 15
Neuroblastoma 1
Wilm
’s TTumor
umor 9
Wilm’s
Rhabdomyosarcoma 2
Osteosarcoma 1
Others 11

Central Nervous System 31
Leukemia 26

Total Cases
92

Lymphoma 12
Neuroblastoma 5
Wilm
’s TTumor
umor 4
Wilm’s
Rhabdomyosarcoma 3
Osteosarcoma 1
Others 15

Lymphoma 8
Neuroblastoma 7
Wilm
’s TTumor
umor 4
Wilm’s
Rhabdomyosarcoma 5
Osteosarcoma 2
Others 17

Total Cases
97

Central Nervous System 19
Leukemia 30

Central Nervous System 22
Leukemia 24
Lymphoma 16
Neuroblastoma 4
Wilm
’s TTumor
umor 7
Wilm’s
Rhabdomyosarcoma 4
Osteosarcoma 6
Others 14

TOTAL DIAGNOSES

Cancer Registry Data

A Six-Year Comparison of Most Frequently Occurring
Diagnoses at Children’s Mercy Hospital

Total Cases
100

Total Cases
85
Total Cases
79

Osteosarcoma
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Osteosarcoma
the-knee amputation and the patient can be fitted with a
Osteosarcoma is the most common primary
prosthesis. Dr. Dale Jarka at Children’s Mercy Hospital
malignant bone tumor in adolescence and young
and Dr. Howard Rosenthal at the Mid-America Sarcoma
adults. The annual occurrence rate in the United States
Institute work closely with the oncology team at
is approximately 5.6 cases per million white children
Children’s Mercy Hospitals and Clinics to provide a
younger than 15 years. The rate is slightly lower
comprehensive approach to the care of our children
among African-American children.
and adolescents diagnosed with osteosarcoma (see
The disease usually occurs in the most rapidly
graph I).
growing segment of the bones (metaphyseal portions)
and peaks during
puberty, suggesting a
relationship between the
CMH Patient Demographics — 1991-2001 (16 Patients) - Graph I
development of this
malignant tumor in
Age Range: 5 to 17
Mean:
11.9
rapidly growing bones.
Median:
13
Osteosarcoma can occur
Male:
7
in any bone, but more
Female:
9
than 60% of cases involve
the knee area (femur and
tibia). Ionizing radiation
SEER: M:F
1.15:1
is the only environmental
CMH:
0.7:1
agent known to cause
osteosarcoma.
Patients typically
Limb
present with bone pain,
Salvage:
12
with or without a soft
Amputation: 3
tissue swelling. The
Age distribution in 16 patients
Missing:
1
average duration of
symptoms is about 3 to 4
months. Imaging studies
show a destructive or sclerotic lesion, usually associated
Staging is determined as follows:
with a soft tissue mass and peri-osteal elevation. Almost
• Low grade:
Stage I
20% of patients present with visible lung metastasis, but
• High grade:
Stage II
historical data indicate that the majority of patients have
• Intra-medullary:
A
microscopic lung deposits at the time of diagnosis. The
• Extra-medullary:
B (majority of patients fall in
diagnosis is established by a biopsy, which shows
the category of IIB)
sarcomatous stroma and osteoid formation. Aggressive
• Distant metastasis:
Stage III
resection of pulmonary nodule(s) is a requirement in
patients who present with overt metastasis.
Today, 60 to 70% of patients achieve long-term
It is essential that an orthopedic surgeon,
survival. Patients with good prognostic factors (lack of
experienced in the management of malignant bone
clinically detectable metastasis at diagnosis and tumor
tumors perform the initial biopsy and coordinate the
kill of more than 98% in response to initial
timing and choice of definitive surgery in collaboration
chemotherapy) have a five-year disease-free survival
with the oncology team. Surgical options include: limb
rate of 75-85%. Patients with poor prognostic features
sparing/salvage procedure, arthodesis (fusion of the
(overt metastasis and inferior response to initial
joint), and rotationplasty (this involves an excision of the
chemotherapy) have less than 30% chance of cure. This
femur with preservation of the lower leg, then the lower
underscores the obvious advantage of early detection/
leg is turned 180 degrees. The foot, which is now
diagnosis. The outcome is also poor for patients who
facing backward, becomes the knee). Rotationplasty
develop recurrent disease while on therapy or who
improves functional ability, as this is similar to a below-
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Osteosarcoma
Survival Function - Graph II
1.0

Pathology

Survival

The pathologist receives biopsies
from patients suspected of having a bone
tumor. It is necessary to confirm and
.8
identify the tumor through the use of
conventional histologic techniques. There
are a number of benign and malignant
.6
bone tumors that occur in children that
must be distinguished from
osteosarcoma. Correlation of the
.4
histology with the location and
radiographic appearance is essential to
the conclusion of a confirmed diagnosis
.2
when biopsies are small and sampling is
Survival Function
limited. Osteosarcomas have a variety
of appearances under the microscope
Censored
0.0
that range from relatively well
0
2
4
6
8
10
differentiated malignant bone tumors
Time (years)
that almost completely recapitulates the
Necrosis more than 95% following the
Overall three year disease free survival:
appearance of normal bone to tumors
initial chemotherapy correlates with
National:
63%
survival:
CMH: 54%
that are very poorly differentiated and
CMH:
CMH survival data was skewed due to a
have almost no resemblance to bone.
>95%: 3 pts
small dataset and the number of
<95%: 5
patients censored (10). The result
In between this range are most
Not reported: 8
however is still within the limits of
osteosarcomas, typically comprised of a
Data pairs are too small to perform log
sampling error.
rank analysis
mixture of malignant cartilage, osteoid
and fibrous tissues. Osteosarcomas
have a range of aggressive or poor
relapse soon after completion of treatment (see graph
prognostic features such as the rare low grade indolent
II).
tumor that arises on the surface of the bone and are
Clinical trials in the 1980s established a role for
well differentiated to the common aggressive tumor that
chemotherapy in the management of this disease that
arises within the metaphyseal region of the long bones
traditionally included surgical amputation only. Most
in the extremities. Vascular invasion by tumor cells is
centers employ a “sandwich” therapy approach by
conspicuous and associated with blood-borne
giving chemotherapy prior to and after the definitive
metastasis to the lungs, that has already occurred at the
surgery. Few small trials have tried to use an intratime of diagnosis in about 20% of the cases.
arterial route to deliver the maximum drug dose
Osteosarcoma can also rapidly spread through the
possible to the primary tumor. Other investigators
medullary space, as well as, the external cortex of the
prefer an up-front surgical resection prior to
bone to infiltrate and destroy the surrounding soft
chemotherapy. Analysis of the results show no
tissue. The pathologist’s assessment of the regional
significant difference in the outcome of these two patient
extent of spread and therapeutic response of the tumor
populations. As a part of the Children’s Oncology
to chemotherapy through careful analysis of amputation
Group (C.O.G.) we follow approved protocols which
and more limited limb-sparing resection biopsies is
utilizes the “neo-adjuvant” method of therapy. This
important information used to determine appropriate
therapy is to administer a 10-12 week of chemotherapy
“post-resection” treatment. Appropriate portions of the
before surgery, aiming to prevent or eradicate any
tumor may also be submitted to research laboratories
possible metastases, improve the patient’s chance for a
for special studies.
successful limb sparing operation, and assess the
tumor’s response to chemotherapy.
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Osteosarcoma
Cytogenetics
Osteosarcoma (OS), a primary bone tumor
derived from primitive bone-forming mesenchyme,
arises from a stem cell capable of differentiating toward
a fibrous tissue, cartilage, or bone, and shares many
features with chondrosarcomas and firbrosarcomas.
A genetic predisposition to OS is suggested in
families with several members who have developed OS.
The strongest pediatric predisposition to OS is found in

more frequently in the extremities than in the general
population. RB is a childhood tumor that arises as a
result of recessive genetic mutations at a gene on
chromosome 13 at band q14 (13q14). The gene is
names RB1 because of its role in the pathogenesis of
retinoblastoma. It is a tumor suppressor gene (TSG)
and as such, both copies of the gene must be lost or
mutated for a tumor to manifest. The RB1 gene is also
implicated in the generation of osteosarcoma even in
patients with no history of retinoblastoma.
TP53 is another TSG implicated in the
pathogenesis of OS. Germline mutations of the p53
gene are responsible for the hereditary Li Fraumeni
syndrome (LFS). Individuals with LFS are predisposed to
multiple tumore types, including OS. Three to four
percent of children with OS have gerline mutations of
p53. Cytogenetic analysis of the tumor cells from
osteosarcoma typically shows a very complex picture
with structural abnormalities of many chromosomes.
While there is no recurring diagnostic chromosome
abnormality in OS, about 30% of tumors show loss of
chromosome 13, deletion of chromosome 13 band
q14, or re-arrangement of band 13q14. Loss of
chromosome 17 or re-arrangement if the short arm of
chromosome 17 (location of the p53 tumor suppressor
gene) is found in 25% of osteosarcoma. Amplification
of oncogenes MDM2 or c-myc is seen approximately
20% of OS. If present, gene amplification is associated
with a more aggressive disease process with higher risk.

Radiology

Amanda
7 years old. Osteosarcoma.

Completed therapy in 2001.
patients with hereditary retinoblastoma (RB). The risk of
developing a secondary tumor for patients with
hereditary RB is estimated to be 8-90% at 30 years. The
majority of second malignancies are sarcomas, and
almost 50% are osteosarcomas.
In hereditary RB, OS occurs 2000 times more
frequently in the skull after radiotherapy and 500 times
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The diagnosis of osteosarcoma is typically made
on the basis of an X-ray examination. CT and MRI
scans are often done following the diagnosis to
determine the extent of the tumor and identify any
potential sites for metastises. A CT scan of the chest is
necessary to determine whether or not the tumor has
spread to the lungs. A nuclear medicine bone scan
helps determine whether or not there are additional
tumors in the skeleton. Patients with osteosarcoma will
visit the radiology department frequently during the
course of the treatment and following to determine their
response to the treatment regimen and to identify any
other complications.

H e m a t o l o g y/
Oncology
Section
Support
Services
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Support Services
The Section of Hematology/
Oncology
The Section of Hematology/Oncology at Children’s
Mercy Hospitals and Clinics has four distinct services
that support the care of children with malignant or
hematologic disorders. The Regional Hemophilia
Center supports seven sites in a five state region to
provide comprehensive treatment for both adult and
pediatric patients with bleeding disorders, as well as
coagulation/thrombosis disorders. The Sickle Cell
Disease Service offers specialized care to this unique
population of patients in an effort
to effectively treat acute and
chronic pain, as well as long
term sequelae related to sickle
cell disease. The Bone Marrow
Transplant Service provides
hematopoeitic stell cell rescue to
patients receiving ablative therapy
and requiring marrow rescue.
This is done utilizing umbilical
stem cells, matched-related
donor cells, and matchedunrelated donor cells. This
service participates in a national
marrow search program and
have cells available to them from
all across the world. The
Oncology Service is dedicated to
the treatment of malignant disorders. Each service has
a designated director of service and the section has a
section chief and a section manager who oversee the
medical, nursing, research, and operations. The
section is comprised of approximately 145 faculty/staff.

unit is equipped with an advanced hepa-filtration air
handling system. In addition, there is a small infusion
area designed to provide treatments after hours and
weekends. In addition to the physicians the staff include
physician’s assistants, advanced practice nurses, nurse
clinicians, specially trained staff nurses, clinical
pharmacists, nursing assistants, Access Representatives,
social workers, child life therapists, music therapist, a
registered dietician and nutrition technician, chaplain,
and a child psychologist. This comprises a unique
multidisciplinary team dedicated solely to hematology/
oncology.
The outpatient clinic is
located in the outpatient building
at Children’s Mercy Hospital on
the second floor and the
inpatient unit is located on the
fourth floor of the newly named
Henson Tower. The Oncology
Service provides a partnership
patient care management model
which includes one attending,
one case manager (advanced
practice nurse/nurse clinician)
and one social worker who
oversee a clearly defined group
of patients. The Bone Marrow
Transplant Service utilizes the
support of physician’s assistants.
The model utilized by the
oncology services has
demonstrated an effective approach to providing a
continuum of care for patients and their families who
encounter numerous health care providers during the
course of their treatment. As a teaching hospital
residents are actively involved in the care of the
oncology patients, as well. In addition, there is a
discharge coordinator whose role is to streamline a
more efficient discharge for the patient being
discharged from the inpatient area. Parent satisfaction
surveys convey a high correlation between satisfaction
and a care model that supports a clearly defined care
team.
All staff nurses in both the inpatient and outpatient
areas are PALS certified, have advanced central line
management training, intense preparation/training in
the handling/administration of chemotherapy.
Caregivers undergo a competency validation for the
support of conscious sedation to support the need to

Jerad
18 years old. Osteosarcoma.
Continuing therapy in 2001.

Oncology Services/Sites
The Oncology Service consists primarily of an
outpatient clinic and an inpatient unit. In addition, care
is provided in collaboration with home care providers.
The Hematology/Oncology clinic served approximately
7900 patients in 2000 with visits ranging from routine
laboratory studies to complex treatments. The inpatient
unit, 4 Henson, had a modal census of 20.5 per day in
2000 with a total bed capacity of 25. These beds are
allocated with 20 dedicated to hematology/oncology
patients and five dedicated primarily to bone marrow
transplant. The unique feature of this unit is the entire
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Support Services
perform invasive procedures in accordance with The
American Academy of Pediatrics. The oncology service
performs between 50-60 procedures each month. There
are times when general (deep) sedation is required to
achieve optimal outcomes and these procedures require
the support of an anesthesiologist and must be done in
the controlled setting of the CMH Procedure Room.
Sedation must be customized to each patient in order to
effectively address the patient’s anxiety and discomfort.
Staff participate in research through the collection of
laboratory specimens, the collection of data, and the
provision of treatment that coincides with a well-defined
protocol/study. Research/data management is a major
focus of the oncology
service which requires the
support of research
coordinators and data
collection/management
experts. Our goal is to
ensure all regulatory
standards are followed and
the most current, up-todate treatment options are
offered to our patients.
In an effort to
continually address the
needs of our patients and
their families we conduct
satisfactions studies. In
2000 a time study was
conducted in the outpatient
clinic that conveyed a less
than 10 minute interval
from the time of
registration to the placement of a patient in an exam
room. Numerous studies were conducted to evaluate
patient/family education which resulted in new
programs to address the educational needs of the newly
diagnosed oncology patient. These include a “Parent
Handbook,” a “Know To Go” questionnaire to identify
whether a patient/family could safely care for their child
upon discharge to home, and a “Family Education
Hour” was developed which provides a classroom
setting for patients/families to learn together.
A satellite pharmacy was implemented in 2000 to
improve administration/delivery times for medication,
as well as, promote safe medication delivery; i.e.
decentralization and a central location for the
preparation of chemotherapy. Our ultimate mission

continues to be to provide each patient and family with
a plan of care that meets their individual needs in a
holistic atmosphere.

Pediatric Hematology/Oncology
Fellowship Program
The fellowship program at Children’s Mercy
Hospital trains the future pediatric hematology/oncology
specialists to conduct patient care and research.
Pediatric hematology/oncology fellows at Children’s
Mercy are fully trained pediatricians who dedicate a
minimum of three years of
training in hematology/
oncology medicine and
research. The first year is
dedicated primarily to
clinical care and becoming
familiar with procedures.
The subsequent two years
are dedicated heavily to
clinical and laboratory
research. Karen Lewing,
MD, our first fellow from
1996-1999, began
research with the enzyme,
“thiopurine
methyltransferase” and has
continued working with the
Children’s Cancer Group
on research projects. Dr.
Lewing is now an attending
with the Hematology/
Oncology Section.
Children’s Mercy Hospital currently has funding for
three fellowship positions.

Our ultimate mission
continues to be to provide
each patient and family with
a plan of care that meets
their individual needs in a
holistic atmosphere.

The Children’s Mercy Hospital
Cancer Care Committee
The Children’s Mercy Hospital Cancer Care
Committee is a standing medical staff committee that is
charged with overseeing the Oncology services within
the hospital. It is chaired by the Director of Oncology
and has both physician and non-physician members
(see member listing). Numerous associated specialties
that also participate in the care of oncology patients are
represented on the committee. It meets quarterly and
reviews the patient acuity, programmatic efforts and
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needs, and quality assurance efforts that are related to
Oncology services.

The Children’s Mercy Tumor
Board
The Children’s Mercy Tumor Boards represent
discussions about newly diagnosed, recurrent, and
unusual oncology patients. All patients diagnosed at
Children’s Mercy Hospital are discussed in this
conference. The conference consists of a review of the
patient’s history,
physical findings at
diagnosis,
laboratory values,
radiological exams,
surgical
interventions, and
pathology findings.
This is followed by a
review of the
patients therapeutic
options, current
therapy, response to
therapy, and
anticipated
prognosis. This is
attended by
physicians including
specialists from
oncology, surgery,
radiology,
pathology,
orthopedic surgery,
otolaryngology,
neurosurgery,
ophthalmology,
neurology, neuropsychology,
rehabilitation medicine, endocrinology, and radiation
therapy. Additionally, nurse specialists, floor and clinic
nurses, nutritionists, pharmacists, child life, chaplaincy,
social workers, and other members of the patient’s
multidisciplinary team are in attendance. This provides
a forum for general review, education, and invited input
and enhances the multidisciplinary team approach for
children with cancer utilized at Children’s Mercy
Hospital. These tumor boards are conducted in
compliance with the American College of Surgeon’s

accreditation requirements.

Psychologist
A psychologist works intimately with the Oncology
Service and is a member of the CMH Section of
Developmental and Behavioral Sciences. There are a
variety of services offered to these patients and their
families which include support to the patient, parents,
and siblings. The psychologist can assist the child and
family in learning how to cope with the medical
diagnosis, hospitalization, and with ongoing
treatment and medical procedures. In addition,
the psychologist can provide information to
parents on age-appropriate ways to talk to the
patient and/or siblings about the diagnosis and
treatment. In 2000, our regimen for promoting
better oral intake of medications was developed
and implemented utilizing the expertise of the
psychologist. Taking “PO” medications can be
a stressor for parents.

Parent-To-Parent
Program
A program
designed to
connect parents
who have been
through the
cancer
experience with
parents of newly
diagnosed
children. The
support one
parent can give
another is immeasurable. The program focuses
on the initial phase of the cancer experience;
however, many of these parents develop strong, longlasting relationships as they journey through the cancer
experience together. These volunteer parents provide a
mission statement “To offer comfort and compassion to
all oncology families, from the comfort and compassion
that we ourselves received.” This program has a social
worker who devotes 20 hours each week to designing
supportive activities, as well as fun events to allow some
distraction from these everyday challenges. These
include: “Pumpkin Patch Run,” “Movie Night Out,”
“Bowling Night Out.” In addition, there is an annual

Jaime
13 years old. Osteosarcoma.
Completed therapy in 2001.
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picnic in the summer and a holiday party at Christmas
time to all patients/families. Many parents volunteer
with these events, as well.

Social Work and Community
Services
There are four full-time and two part-time social
workers dedicated to the Hematology/Oncology Section.
The primary focus of this team is to assist the patient
and family in understanding the impact the diagnosis of
cancer will have on their family dynamics and life style.
Social workers are skilled in counseling patients,
parents, and siblings with issues of grief, anger, and
overall well-being. They
have a fundamental
knowledge of pediatric
hematology/oncology
which provides them with
the framework to support
the family in
comprehending the
diagnosis and treatment
plans, and, as important,
the non-medical
ramifications associated
with the treatment of
childhood cancer. The
social workers, as well as,
other health care team
members assist the families
in recognizing their role as
partners in the care of their
child and in recognizing the community support
available to them. The utilization of this community
support is crucial to the success of any treatment plan.

ongoing support associated with the diagnosis and
treatment of childhood cancer and hematological
disorders. Each of these therapists are master’s
prepared and assist family members and health care
team members on effective strategies/interventions that
allow patients to make choices and allow them a sense
of self-expression. Medical play utilizing art, story
telling, and music are important elements in effectively
educating and preparing the pediatric patient for
invasive and traumatic procedures utilizing ageappropriate measures. Sibling support is an important
part of the day to day activities of these therapists, as
well. The sibling can be instrumental in assisting the
pediatric patient through the coping process. Both
Child Life and Music
therapists are available in
the outpatient and inpatient
areas and they are capable
of continuing an
intervention beyond the
hospital admission.

The impact of play and music
has been demonstrated to
have a positive effect in the
treatment of childhood
cancer.

Child Life Therapist/Music
Therapist
One of the greatest challenges of working with
children is the ability to reach them at their
developmental and cognitive level. The impact of play
and music has been demonstrated to have a positive
effect in the treatment of childhood cancer. The Section
of Hematology/Oncology is provided two full-time child
life therapists and 10 hours each week of a music
therapist. This talented group work with patients,
parents, and siblings to aid in the adjustment and

Chaplaincy

One full time
chaplain is assigned to the
hematology/oncology
section to support the
spiritual needs of the
patients and their families
and there is a chaplain
available 24 hours a day to
all patients. The diagnosis
of osteosarcoma can
present significant religious/spiritual questions for the
patient and family which can lead to a crisis of faith as
families try to sort out the questions and emotions that
accompany a diagnosis of cancer. Personal faith and
the faith of the community can be a tremendous source
of hope and strength during this challenging time. In
addition to supporting the patient and family, the
chaplain is an integral part of the support system for the
staff who, too, can struggle with spiritual/religious and
ethical issues. Children’s Mercy Hospital strives to
support all religious affiliations.
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Psychology

CMH Connection

Children’s Mercy Hospitals and Clinics believes
that the physical and emotional aspects of a child’s care
are tightly connected, particularly when diagnosed with
childhood cancer. A full-time psychologist supports the
hematology/oncology section in providing support to
the patient, parents, and siblings. This support ranges
from strategies for coping with a new diagnosis to
interventions to improve medication palatability/intake,
which is extremely challenging in the pediatric patient
population. This psychologist is a member of the
hematology/oncology
team and the Section of
Developmental and
Behavioral Sciences at
CMH. The Children’s
Mercy Cancer Center
provides funding to
support this position.
The majority of
psychological services
are provided on an
outpatient basis. The
developmental and
behavioral sciences
section supports the
mentoring/education of
psychology students, as
well. Outpatient
appointments are
available by calling (816)
234-3674.

This is a unique program designed to support the
physicians and staff who care for the patients and
families diagnosed with childhood cancer and blood
disorders. This program is offered three times each
year which includes eight one-hour sessions. The focus
of these sessions is promoting the well-being of the staff
that provide care to children and families with chronic,
life-threatening diseases, as well as, coping with death
and dying. The overall goal of this program is to take
care of the caregivers who take care of the patients and
families.

Pharmacy
The decentralization
of pharmacy to the
patient care area
demonstrates a strong
multidisciplinary
approach to patient care.
The Section of
Hematology/Oncology is
supported by two clinical
pharmacists, one
satellite pharmacist, and
one pharmacy
technician. Each of
these staff is trained in
the safe and proper
handling of
chemotherapy in
accordance with current
safety regulations. A
satellite pharmacy was developed in 2000 to support the
unique needs of the hematology/oncology patient
population and to integrate pharmacy more closely into
the team. This integration is closely linked to improved
medication delivery/administration outcomes. This
satellite is located on 4 Henson Tower and supports
both the inpatient and outpatient service sites.

In Memory of Lindsey.
Lindsey (left) was 15 years old.
She passed away October 7, 2001

Nutrition Services
Nutrition and patient outcomes related to pediatric
oncology have been linked closely over the years.
Nutrition is an important component to aid in the
prevention and correction of nutritional deficiencies,
thus improving the overall well-being of the child
undergoing the treatment of cancer. There is one fulltime and one part-time registered dietician and a
nutrition technician who support the Section of
Hematology/Oncology. This includes nutritional
assessments, interventions, as well as participation in
nutrition focused research/data collection. The nutrition
service provides support in all service areas to include
inpatient, outpatient, and home care.
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Our Research
CMH IRB No.
7-2-01

Study

CHILDREN’S ONCOL
OG
Y GROUP STUDIES
ONCOLOG
OGY
Acute LLymphoblastic
ymphoblastic LLeukemia
eukemia
P96 10-64

1961

Treatment of Patients with ALL with Unfavorable Features

P00 07-55

1991

Escalating Dose of Intravenous Methotrexate Without Leucovorin Rescue vs Oral Methotrexate
and Single vs Double Delayed Intensification for Children with Standard Risk ALL

Acute Mylogenous Leukemia
P96 10-65

2961

A Phase III Study in Children with Untreated AML or MDS

P99 08-96

A2971

Treatment of Children with Down Syndrome and Acute Myeloid Leukemia, Myelodysplastic
Syndrome and Transient Myeloproliferative Disorder

P00 07-69

C9710

Phase III Randomized Study of Concurrent ATRA and Chemotherapy with or without Arsenic
Trioxide for Patients with Untreated Promyelocytic Leukemia

Biopathology
P96 12-85

B942

Detection of Minimal Residual Disease in Children Receiving Therapy for AML or MDS

P95 03-22

B944

Biology Studies in Childhood Hodgkin’s and Non-Hodgkin’s Lymphoma

P98 11-88

B945

The Genetic Epidemiology of 11q23 Leukemia in the Young

P94 10-63

B947

Protocol for Collection of Biology Specimens for Research Studies

P98 05-36

B951

Pharmacological Studies of L-Asparaginase in Pediatric Patients with ALL or Lymphomas

P99 01-07

B957

Genetic Etiology of Acute Leukemia in Down Syndrome

P98 11-90

B961

Prognostic Significance of Ki-67 Proliferative Index Utilizing the MIB-1 Antibody in Low Grade
Gliomas in Young Children

P98 11-90

B971

Molecular Cytogenetic Determination of Prognostic Parameters in Childhood Primitive
Neuroectodermal Tumor

P98 05-37

B9710

Gene Therapy for Ph+ ALL

P98 11-89

B972

Immune Status and Activation in Children Participating in CCG 2961, A Phase II Trial in Children
with Untreated AML or Myelodysplastic Syndrome

B974

Prevalence and Clinical Implication of Chromosome Band 1p36 Deletion and the Role of
Imprinting in Neuroblastoma

P99 05-75E

B975

Molecular Markers of Malignant Gliomas of Childhood

P99 03-37

B9804

Clinical and Biological Predictors of Therapy Related Leukemia

P99 04-47

D9902

A Group Wide Protocol for Collecting and Banking Pediatric Center Research Specimens

P99 10-116

P9851

Biology Studies in Osteosarcoma

Brain TTumors
umors
P98 11-84
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CCG 99701 An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy
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Followed by Adjuvant Chemotherapy in Children with Newly Diagnosed, High Risk Central
Nervous System Embryonal Tumors
P98 11-85

CCG 99703 A Pilot Study of Intensive Chemotherapy with Peripheral Stem Cell Support for Infants with
Malignant Brain Tumors

P97 06-31

A9952

Chemotherapy for Progressive, Low Grade Astrocytoma in Children Less than Ten Years Old

Experimental Therapeutics – New Agents
P94 02-06

0923

A Trial of Carboxypeptidase-G2 for the Management of Patients with Intrathecal Methotrexate
Overdose

P99 12-120

0954

A Phase I Study of Gemcitabine in Children with Refractory Solid Tumors

P97 06-30

0962

A Phase II Study of Docetaxel in Children with Recurrent Solid Tumors

P99 03-35

09709

A Phase I Study of Fenretinide in Children with High Risk Solid Tumors

P99 06-80

09713

A Phase II Study of Continuous 21 Day Infusion of Topotecan in Children with Relapsed Solid
Tumors

P99 02-26

09714

A Phase II Study of Oral Topotecan in Relapsed Acute Childhood Leukemia

P99 06-81

09716

A Phase II Trial of the Combination of Carboplatin and RMP-7 in Childhood Brain Tumors

P99 04-46

09717

A Phase I Study of TPO Plus G-CSF Following I.C.E. in Children with Recurrent or Refractory Solid
Tumors

P00 05-42

A0003

A Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients with Refractory
Leukemia or Lymphoma

P98 11-83

A09705

A Phase II Evaluation of Intravenous Navelbine in Recurrent or Refractory Pediatric Malignancies

P00 10-88

ADVL0011

A Phase I Study of Temozolomide and CCNU in Pediatric Patients with Newly Diagnosed
Incompletely Resected Non-Brainstem High-Grade Gliomas

P99 12-121

P9423

A Phase I Cooperative Agreement trial of Mitroxantrone, Etoposide and PSC-833 In Patients with
Relapsed and Refractory Acute Leukemia

P97 11-77

P9673

A Phase II Study of Compound 506 in Patients with Refractory T-Cell Malignancies

P99 12-138

P9761

A Phase II Trial of Irinotecan in Children with Refractory Solid Tumors

P00 08-73

P9962

A Phase II Study of Topotecan in Patients with Refractory Meningeal Malignancies

P00 09-83

P9963

A Phase II Trial of Rebeccamycin Analogue in Children with Solid Tumors

P00 02-15

P9970

A Trial of Irinotcan and Cisplatin in Children with Refractory Solid Tumors

P00 09-84

P9971

A Trial of Irinotecan Plus Vincristine in Children with Solid Tumors

01 03-24

P9972

A Phase I Study of ET-743 in Pediatric Refractory Solid Tumors

P00 04-34

P9973

A Phase I Study of STI571 Ph+ Leukemia

Epidemiology
P99 08-87

A0026

A Case Control Study of Risk Factors for Wilms’ Tumor

P98 05-38

AE23

Epidemiology of Down Syndrome-Leukemia and Down Syndrome
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P99 08-86

AE24

Epidemiology of Infant Leukemia

P99 05-67

AE25

Pesticide Exposure and Markers of VDJ Recombination in Children with Lymphoma

P90 10-39

E13

Case Control Study of Hodgkin’s Disease in Children

P96 12-87

E22

Epidemiology of Malignant Germ Cell Tumors in Children

Ewing Sarcoma
01 03-25

AEWS0031 Trial of Chemotherapy Intensification Through Interval Compression in Ewing Sarcoma and
Related Tumors

Germ Cell TTumors
umors
P00 07-68

P9749

Pilot Intergroup Study of High-Dose Cisplatin, Etoposide and Bleomycin Combined With
Amifostine in Children with High-Risk Malignant Germ Cell Tumors

Hepatic TTumors
umors
P99 05-66

P9645

Phase III Intergroup Protocol for the Treatment of Children with Hepatoblastoma

Late Effects
P96 11-72

CCG 4941L National Wilms’ Tumor Late Effects Study

P99 08-88

CCG L9714 Quality of Life Following Successful Therapy of AML: A Comparison of Marrow Transplant and
Chemotherapy

Hodgkin/Non-Hodgkin LLymphoma
ymphoma
P98 11-87

A5962

A Pilot Study of Peripheral Blood Stem Cell Transplantation following CBV Preparative Therapy
in Children with Relapsed or Primarily Refractory HD & NHL

Relapsed Leukemia
P98 03-16

CCG 2951 AML Salvage Therapy for Patients in First Relapse or Who Fail to Achieve Initial Remission or
Who Develop AML as a Second Malignant Neoplasm

Neuroblastoma
P00 04-36

A0935A

A Phase I Study of ch14.18 with GM-CSF and IL-2 in Children with NBL and Other GD2 Positive
Malignancies Immediately Post ABMT or PBSC Rescue

P98 05-34

A3961

Treatment for Infants and Children with Intermediate Risk Neuroblastoma

P00 09-85

ANBL00B1 Neuroblastoma Biology Studies

P96 12-84

P9462

Randomized Treatment of Recurrent Neuroblastoma with Topotecan Regimens

P98 05-35

P9641

Primary Surgical Therapy for Biologically Low-Risk Neuroblastoma

Non-Hodgkin LLymphoma
ymphoma
P00 07-70

22

A5971

A Randomized Phase II Study for the Treatment of Newly Diagnosed Disseminated
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Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma
Osteosarcoma
P99 10-115

P9754

Protocol for Patients with Newly Diagnosed, Non-Metastatic Osteosarcoma

Diagnostic/Imaging
P98 03-17

CCG R9701 Use of Thallium Scintigraphy in Assessing Therapeutic Response to Pediatric Ostoegenic
Sarcoma to Chemotherapy

Wilms’/Kidney TTumors
umors
P95 10-76

4941

National Wilms’ Tumor Study V – Therapeutic Trial and Biology Study

P99 03-38

4942

National Wilms’ Tumor Study 5 – Treatment of Relapsed Patients

Soft Tissue Sarcoma/Rhabdomyosarcoma
P99 10-112

D9602

Actinomycin D and VCR with or without CPM and RT for Newly Diagnosed Patients with Low Risk
Embryonal/Botryoid Rhabdomyosarcoma

P99 10-114

D9802

A Phase II Study of CPT-11 Followed by Multimodal, Multiagent Therapy for Patients with Newly
Diagnosed Stage 4/Group IV Rhabdomyosarcoma

P99 12-136

D9803

Randomized Study of VCR, Actinomycin-D and CPM vs VAC Alternating with VCR, Topotecan,
and CPM for Patients with Intermediate Risk Rhabdomyosarcoma

Second Malignancies
P99 05-53

AS9801

A Study of Second Malignant Neoplasms Following Childhood Cancer

Supportive Care
P99 05-52

SPONSOR

AS973

Randomized Comparison Between Antibiotics Alone and Antibiotics Plus G-CSF in Pediatric
Patients with Chemotherapy Induced Febrile Neutropenia

STUDIES – ONCOL
OG
Y
ONCOLOG
OGY

P00 03-26

Dose-Ranging Trial Utilizing a Recombinant Urokinase in the Treatment of Occluded Central
Venous Catheters Primarily in Oncology Subjects

P00 10-97

Cord Blood Transplantation Study (COBLT): Unrelated Donor Umbilical Cord Blood as an
Alternate Source of Stem Cells for Transplantation

P96 04-33

Compassionate Release for Erwinia L-Asparaginase

P99 09-99

A Study to Assess the Safety, Dose Conversion and Titration of DuragesicÒ (fentanyl
transdermal system) in Pediatric Patients with Chronic Pain Requiring Opioid Therapy

P99 12-119

An Open Label, Non-Comparative Study of FK463 for the Treatment of Invasive
Aspergillosis

P00 07-58

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly
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ProcritÒ on Anemia and Quality of Life in Children with Malignant Solid Tumors or Hodgkin’s
Disease Undergoing Myelosuppressive Chemotherapy
P00 07-57

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly
ProcritÒ on Anemia and Quality of Life in Children with Acute Lymphocytic Leukemia or
Non-Hodgkin’s Lymphoma Undergoing Myelosuppressive Chemotherapy

P99 02-20

Compassionate Use of SR29142 for Prevention or Treatment of Hyperuricemia

P99 02-23

An Open Label, Non-Comparative Protocol for the Emergency Use of Voriconazole in patients
with Life Threatening Invasive Mucoses who are Failing on Currently Available Antifungal Agents

BONE

MARROW

TRANSPLANT

STUDIES

P97 10-71

Dual Cycle High-Dose Chemotherapy with Peripheral Blood Stem Cell Rescue for Patients with
Recurrent and Progressive Brain Tumors

P96 09-58

Treatment of Lysosomal and Peroxisomal Inborn Errors of Metabolism by Bone Marrow
Transplant

P99 10-106E

Biology of Chronic Graft versus Host Disease

P96 05-44

High-Dose Thiotepa, VP-16 and Cyclophosphamide with Stem Cell Rescue for Pediatric Patients
with High-Risk, Malignant Solid Tumors

P95 07-48

Use of Umbilical Cord Blood as a Source of Progenitor Cells for Myeloablative Therapy Rescue

P99

Preemptive Use of Aerosolized Ribavirin in the Treatment of Asymptomatic Marrow
Transplantation Patients Testing Positive for RSV

P00 06-49

Ex Vivo T-Cell Depletion for GvHD Prophylaxis in Related Haplo-Identical Allogeneic Stem Cell
Transplant Recipients

P99 12-125

Cytokine Mobilized Allogeneic Peripheral Stem Cell Transplantation in Children

P00 10-97

Cord Blood Transplantation Study (COBLT): Unrelated Donor Umbilical Cord Blood as an
Alternative Source of Stem Cells for Transplantation

STUDIES AWAITING CMH INSTITUTIONAL REVIEW BOARD APPROVAL (as of 7-01)
Quality of Life Among Childhood Leukemia Patients
COG

A3973

COG

ADVL0017 A Phase I Study of Flavopiridol in Patients with Relapsed or Refractory Solid Tumors or
Lymphomas

COG

ADVL0022

COG

AHOD00P1 A Pilot Study of re-Induction Chemotherapy with Ifosfamide and Vinorelbine in Children
with Relapsed or Refractory Hodgkin Disease

COG

P9934
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A Randomized Study of Purged vs Unpurged Peripheral Blood Stem Cell transplant Following
Dose Intensive Induction Therapy for High Risk Neuroblastoma

A Phase II Study of Gemcitabine in Children with Relapsed ALL or AML

Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Limited to the Posterior
Fossa And Primary Site for Children Greater than 8 months and less than 3 years with
Non-Metastatic Medulloblastoma
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Introducing Our New Logo

The Children’s Mercy Cancer Center was founded in 1988 to care for children with cancer and
their families by providing support for their physical, emotional, and environmental needs. The
slogan has always been “Tough Fight! Tough Kids!” to symbolize what patients are going
through and what they are. In 2001, it was time for a new look. So we decided to give
Children’s Mercy Hospital’s beloved Mercy Bear a new, tougher look that would fully represent
the mission of the Cancer Center. We hope our new look will be an inspiration to our patients,
families and friends for many years to come!
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